Videos

James Hamrick, MD, MPH, discusses the ways in which incorporating AI into cancer care can improve the timeliness of care for patients, nudge providers to use novel therapies in practice, and reduce inequities in health care.

Rebecca Maniago, PharmD, BCOP, discusses the impact that AI-enabled clinical decision support will have on clinical pathways, as well as the ways in which technology is playing a large role in the current landscape of oncology care.

Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.

Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.

Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.

Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.

Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.

At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...

Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...